Showing results (141-150 of 254) with videos related to
Sort By:
Pageof 26
Journal of the American Academy of Dermatology|December 15, 2010
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trialAlexa B Kimball, Kenneth B Gordon, Richard G Langley, et al.Dermatology and Therapy|January 29, 2021
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated ComorbiditiesAlan Menter, Gerald G Krueger, So Yeon Paek, et al.Journal of Drugs in Dermatology : JDD|August 3, 2007
Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgarisJoel Schlessinger, Alan Menter, Michael Gold, et al.Anais Brasileiros De Dermatologia|August 28, 2015
Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas diseaseCristián Navarrete-Dechent, Daniela Majerson, Marisa Torres, et al.Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditionsElizabeth G Wilder, Jillian Frieder, Suraj Sulhan, et al.Human Molecular Genetics|August 3, 2011
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAomeCailin E Joyce, Xiang Zhou, Jing Xia, et al.American Journal of Clinical Dermatology|February 26, 2017
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE StudyCarle Paul, Craig Leonardi, Alan Menter, et al.Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.Journal of the American Academy of Dermatology|March 12, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trialAlan Menter, Matthias Augustin, James Signorovitch, et al.Pageof 26